Purpose

Amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) is a rare clinical entity, in which both disorders are variably associated in the same patient or within the family. This adult-onset disorder, which is rapidly fatal, occurs in some families with autosomal dominant (AD) transmission and age-dependant penetrance. Two studies have provided evidence for linkage of this condition to chromosomes 15 (in a single family) and 9 (in five families). However, none of these loci have been yet confirmed. Through a national network of 10 centres with specialists for FTD and/or ALS, we have identified 35 probands with ALS-FTD, including 13 with a family history consistent with AD inheritance.

Mutations in the SOD1 and tau genes, respectively responsible for autosomal dominant forms of ALS and FTD, will be excluded by direct sequencing. We will then extend the pedigree of the 13 autosomal dominant families to all consenting first, second and eventually third degree relatives, using well defined criteria for FTD and ALS. The same strategy will be applied to newly identified families during the course of the project (at least, seven families with AD inheritance expected). Linkage studies will be performed in the 20 families using markers from the two candidate regions on chromosomes 9 and 15. Then, refinement of the candidate region will be obtained by analyzing the linked families with a high density of microsatellite markers. This should lead to the refinement of the candidate regions, allowing to search for mutations in candidate genes. Genes located within the critical regions will be prioritized for their analysis by sequencing, according to their expression in the nervous system and to their function.

Once the responsible gene(s) will be identified, it will then possible to define its spectrum of mutations and to establish genotype/phenotype correlations. Alternatively, if none of the candidate regions is confirmed, a genome wide search will be performed, allowing to identify one or more loci for ALS-FTD. The same strategy would then be applied to identify the corresponding gene(s). This project should contribute for identifying the molecular basis of this devastating disorder with practical consequences for genetic counselling in ALS-FTD families, and with the perspective of elucidating the pathophysiology of this disorder.


Condition Phase
Frontotemporal Dementia
Amyotrophic Lateral Sclerosis
Phase I

Genetics Home Reference related topics:   amyotrophic lateral sclerosis  

MedlinePlus related topics:   Amyotrophic Lateral Sclerosis   Dementia  

U.S. FDA Resources

Study Type:   Observational
Study Design:   Case Control, Retrospective
Official Title:   Genetic Linkage in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Whole blood


Enrollment:   400
Study Start Date:   September 2002
Study Completion Date:   June 2007

Groups/Cohorts
1
Patients with frontotemporal dementia and amyotrophic lateral sclerosis
2
Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis

Detailed Description:

The objective of this study without direct individual benefit is to confirm the linkage with one or another region of the two identified regions (chromosomes 9 and 15) or to identify a new implicated chromosomal region, and then to reduce the linkage interval in order to identify the responsible gene(s) and characterize the mutations with the study of at least 9 families with FTD and ALS.

  Eligibility
Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample

Study Population

Patients and relatives coming in outcome clinics. They are all volunteers and agree to give a blood sample and signing an informed consent explaining the study.


Criteria

Inclusion Criteria:

  • ALS with FTD, "pure" FTD but with knowledge of relatives with ALS-FTD or "pure" ALS, "pure" ALS but with knowledge of relatives with ALS-FTD or "pure" FTD (not carriers of a mutation in the tau and SOD1 genes), relatives signing the informed consent

Exclusion Criteria:

  • Minors, persons refusing to sign the informed consent
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159198

Locations
France
Hôpital Pitié-Salpêtrière    
      Paris, France, 75013
Hôpital Pontchaillou    
      Rennes, France, 35000
CHU de la Côte de Nacre    
      Caen, France, 14000
Hôpital de l'Archet    
      Nice, France, 06000
Hôpital La Timone    
      Marseille, France, 13005
Hôpital Pitié-Salpêtrière - Centre du Langage-Neuropsychologie    
      Paris, France, 75013
Centre Hospitalier    
      Saint-Brieuc, France, 22000
Centre Hospitalier Universitaire de Lille    
      Lille, France, 59000
Hôpital Pitié-Salpêtrière - Fédération de Neurologie    
      Paris, France, 75013
Hôpital Sainte-Marguerite    
      Marseille, France, 13009
Hôpital Purpan    
      Toulouse, France, 31000
Hôpital Civil    
      Strasbourg, France, 67000
Hôpital Bellevue    
      Saint-Etienne, France, 42000
Hôpital Guillaume et René Laënnec    
      Nantes, France, 44000
Hôpital Charles Nicolle    
      Rouen, France, 76000

Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Investigators
Principal Investigator:     Alexis Brice, MD     Assistance Publique - Hôpitaux de Paris, University Paris 6    
France
Hôpital Pitié-Salpêtrière    
      Paris, France, 75013
Hôpital Pontchaillou    
      Rennes, France, 35000
CHU de la Côte de Nacre    
      Caen, France, 14000
Hôpital de l'Archet    
      Nice, France, 06000
Hôpital La Timone    
      Marseille, France, 13005
Hôpital Pitié-Salpêtrière - Centre du Langage-Neuropsychologie    
      Paris, France, 75013
Centre Hospitalier    
      Saint-Brieuc, France, 22000
Centre Hospitalier Universitaire de Lille    
      Lille, France, 59000
Hôpital Pitié-Salpêtrière - Fédération de Neurologie    
      Paris, France, 75013
Hôpital Sainte-Marguerite    
      Marseille, France, 13009
Hôpital Purpan    
      Toulouse, France, 31000
Hôpital Civil    
      Strasbourg, France, 67000
Hôpital Bellevue    
      Saint-Etienne, France, 42000
Hôpital Guillaume et René Laënnec    
      Nantes, France, 44000
Hôpital Charles Nicolle    
      Rouen, France, 76000
Assistance Publique - Hôpitaux de Paris
Principal Investigator:     Alexis Brice, MD     Assistance Publique - Hôpitaux de Paris, University Paris 6    
  More Information

Related Info  This link exits the ClinicalTrials.gov site
 

Publications of Results:

Study ID Numbers:   CRC01107, P011023
First Received:   September 7, 2005
Last Updated:   November 21, 2007
ClinicalTrials.gov Identifier:   NCT00159198
Health Authority:   France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Amyotrophic lateral sclerosis  
Frontotemporal dementia  
Mutations spectrum  
Linkage studies  
Genetic epidemiology  

Study placed in the following topic categories:
Pick Disease of the Brain
Frontotemporal dementia
Spinal Cord Diseases
Brain Diseases
Neurodegenerative Diseases
Aphasia, Primary Progressive
Signs and Symptoms
Neuromuscular Diseases
Mental Disorders
Primary progressive aphasia
Dementia
Motor Neuron Disease
Neurobehavioral Manifestations
Delirium
Speech Disorders
Aphasia
Central Nervous System Diseases
Language Disorders
Sclerosis
Degenerative motor system disease

Additional relevant MeSH terms:
Pathologic Processes
Pick Disease of the Brain
Nervous System Diseases
Aphasia, Primary Progressive

Source: National Library of Medicine (NLM) July 09, 2008